Altimmune to Present at the 2020 NASH-TAG ConferenceHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Altimmune to Present at the 2020 NASH-TAG ConferenceGlobeNewswireJanuary 7, 2020ReblogShareTweetShareGAITHERSBURG, Md., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (ALT), a clinical-stage biopharmaceutical company, today announced an oral presentation at the 2020 NASH-TAG Conference being held on January 9-11, 2020 in Park City, Utah. Details for the oral presentation are as follows:Title:     ALT-801, a GLP-1/Glucagon Dual Receptor Agonist, Shows Superior Improvement in Key NASH Endpoints in a Biopsy-Confirmed DIO Mouse ModelPresenter:       Scott Harris M.D., Chief Medical Officer of Altimmune. Inc.            Date/Time:      January 10, 2020 at 11:15 a.m. MST Location:         Renoir Ballroom, The Chateaux Deer ValleyA poster with the same title will also be presented in the Renoir Ballroom, Chateau Deer Valley for the duration of the conference.A copy of the presentation materials will be accessible on the Events section of the Altimmune website.About NASH-TAG 2020The NASH-TAG Conference is designed to bring together clinicians and researchers in academia and the pharmaceutical industry for a focused interactive educational update highlighting the most relevant advances and challenges in the diagnosis and therapy of non-alcoholic steatohepatitis (NASH) and liver fibrosis. NASH-TAG 2020 will take place over two days, providing attendees an understanding of current and future directions in diagnostic procedures, prospects and challenges in drug discovery and development for both NASH and liver fibrosis. Internationally renowned faculty will assist in the development of the educational content and will serve as faculty at the conference. The conference is widely attended by industry and subject matter experts.About AltimmuneAltimmune is a clinical stage biopharmaceutical company focused on developing treatments for liver disease and immune modulating therapies. Our diverse pipeline includes next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoVAX™ and NasoShield™). For more information on Altimmune, please visit www.altimmune.com. Contacts
Will Brown   Ashley R. Robinson
Chief Financial Officer   Managing Director LifeSci Advisors
Phone: 240-654-1450   Phone: 617-535-7742
Email: wbrown@altimmune.com   Email: arr@lifesciadvisors.com ReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextCoronavirus latest news: 'Just a matter of time' until outbreak hits UK as cases spread across EuropeThe TelegraphCoronavirus: Football games and concerts could be banned for two months if pandemic hits UK, says chief medicThe Independent"I quit drinking for a month and this is how it affected my liver"CosmoBiotech Stock Roundup: MRNA Surges, Pipeline Updates from INCY, HRTX & NGM BioZacksCoronavirus Outbreak Maps Rooted in HistoryCity Lab NonHostedBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance Video'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo FinanceMost face masks won’t protect you from the coronavirusYahoo FinanceRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatch